Video

The Evolution of PARP Inhibitors in Ovarian Cancer

Cristiana Sessa, M.D., of the Oncology Institute of Southern Switzerland, discusses the evolution of how PARP inhibitors are used to treat ovarian cancer.

Christiana Sessa, M.D., head of Phase 1-2 Unit and Pharmacology, vice head of Medical Oncology and Head of Clinical Research, Oncology Institute of Southern Switzerland, discusses the evolution of how PARP inhibitors are used to treat ovarian cancer.

Initially, PARP inhibitors were used only in patients who had BRCA1/BRCA2 mutations. However, they then showed activity in patients with high-grade serous ovarian cancer, and in those with what Sessa calls “genomic scarring,” meaning they have DNA damage that cannot be repaired.

Currently there, are three FDA-approved PARP inhibitors in the ovarian cancer space: Lynparza (olaparib), Zejula (niraparib) and Rubraca (rucaparib).

Related Videos
Although late-stage kidney cancer generated poor survival rates for over two decades, significant progress is being made in the treatment of the disease.
There are a number of reasons why patients with cancer are encouraged to enroll in clinical trials, Dr. Michael J. Pishvaian explained.
Use of NeuroSAFE to guide nerve sparing during robot-assisted radical prostatectomy improved patient-reported erectile function.
Adolescent and Young Adult Cancer Awareness Week sheds light on the financial hardships young cancer survivors face, including debt and limited assistance.
CURE spoke with Dr. William C. Huang about what kind of team may be required to treat a patient with metastatic kidney cancer.
Image of woman.
Image of woman.
Image of woman.
Image of man wearing baseball cap backwards.
Image of smiling doctor.
Related Content